When the Shortage Ends, So Does the Copy: The GLP-1 Compounding Wind-Down Explained

Compounded semaglutide and tirzepatide were never approved copies of Ozempic, Wegovy, Mounjaro, or Zepbound. They were legal for a specific reason: federal law allows pharmacies to make a version of a drug that is on the FDA's official shortage list. When the FDA determined that those shortages were resolved, at the end of 2024 for tirzepatide and in February 2025 for semaglutide, the legal basis for mass compounding fell away, and the agency set fixed dates by which the copies had to stop. The FDA has described this transition in its statement clarifying policies for compounders as the national GLP-1 supply stabilized. This article explains the mechanism, not a recommendation, and it is educational rather than medical advice.

Why compounded GLP-1 drugs appeared at all

The demand for semaglutide and tirzepatide outran the manufacturers' ability to fill vials and pens. For an extended stretch, the FDA listed these products as being in shortage. That listing matters because of two sections of the Federal Food, Drug, and Cosmetic Act.

Section 503A covers traditional pharmacy compounding, where a licensed pharmacy prepares a medication for an individual patient. Section 503B covers outsourcing facilities, which produce larger batches under stricter manufacturing standards. Both sections generally prohibit compounding a drug that is "essentially a copy" of a commercially available, FDA-approved product. Shortage status is the exception. While a drug sits on the shortage list, that copy prohibition is relaxed, which is what opened the door to widely available compounded GLP-1 products marketed through clinics and telehealth platforms.

So the availability was not a sign that anyone had reviewed these compounded versions for safety and effectiveness. It was a downstream consequence of a supply gap in the approved products.

What "resolved" triggered

A shortage listing is not permanent. The FDA reassesses supply, and when it concludes that a manufacturer can meet national demand, it removes the drug from the list. That single administrative act reverses the legal logic above: with no shortage, the copy prohibition applies again.

For tirzepatide, the FDA determined the shortage was resolved and, after reconsidering its decision in response to litigation, reaffirmed that finding on December 19, 2024. For semaglutide, the agency's decision memorandum dated February 21, 2025 concluded the injectable shortage was resolved. The FDA published declaratory orders documenting each determination.

Rather than demand that every pharmacy stop overnight, the FDA announced periods of enforcement discretion, meaning windows during which it did not intend to act against compounders for these copies. The dates were staggered by facility type. For tirzepatide, 503A pharmacies had until February 18, 2025, and 503B outsourcing facilities had until March 19, 2025. For semaglutide, 503A pharmacies had until April 22, 2025, and 503B facilities had until May 22, 2025. After those dates, compounding these products as copies of the brand-name drugs no longer fell within the shortage exception.

A useful way to read this: the legality was always tied to a list, not to the molecule. The drug did not change. Its regulatory status did.

Why the FDA treated the copies as a safety matter

The agency's concern is grounded in a structural point. An FDA-approved drug has passed the agency's review for safety, effectiveness, and manufacturing quality. A compounded product has not. In its safety communication on unapproved GLP-1 drugs used for weight loss, the FDA described specific problems it observed.

The agency reported adverse-event reports linked to compounded versions, including dosing errors, where patients drew incorrect amounts from multi-dose vials and, in some cases, took many times the intended dose. It flagged inconsistency in the active ingredient itself, including use of different salt forms such as semaglutide sodium or semaglutide acetate rather than the base molecule studied in the approved products. It also noted that federal law does not require state-licensed pharmacies to report adverse events, so problems tied to compounded versions are likely underreported. None of these are hypothetical risks of the category; they are things the FDA says it actually saw.

The regulatory bottom line the agency states is narrow. Compounded drugs are intended for patients whose medical needs cannot be met by an approved product, obtained by prescription and filled at a state-licensed pharmacy, not marketed as a routine, cheaper substitute for an approved medicine.

A separate 2026 development that is easy to misread

In April 2026, the FDA announced it would remove a group of peptides from Category 2 of its 503A bulk drug substances list, and it scheduled a Pharmacy Compounding Advisory Committee meeting to consider whether some of them should be evaluated for the list.

The wording invites confusion, so precision matters here. Removal from a "do not compound" category is not approval, is not placement on the authorized bulks list, and is not permission to compound. An advisory committee recommendation is non-binding, and any change to what pharmacies may lawfully compound would still require formal notice-and-comment rulemaking. Naming a peptide in this context only illustrates its regulatory status; it says nothing about whether using it is safe or beneficial. FDA-approved, 503A/503B-compounded, and research-only are three distinct legal states, and a product can move between administrative categories without ever becoming an approved medicine.

The durable lesson

The GLP-1 compounding episode is a clean illustration of how supply, not the merits of a copy, governed access. A shortage listing temporarily suspended a prohibition; resolving the shortage restored it; and enforcement-discretion deadlines gave the market a defined runway to wind down. For anyone reading future headlines about a compounded version of a popular drug, the operative question is not whether it exists or is inexpensive, but whether it is an approved product, a compounded preparation permitted only under specific conditions, or something with no approved status at all. Those categories carry very different guarantees.